Literature DB >> 10927139

Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy.

H Langendijk1, E Thunnissen, J W Arends, J de Jong, G ten Velde, R Lamers, D Guinee, J Holden, M Wouters.   

Abstract

PURPOSE: The purpose of this study was to assess the prognostic value of the expression of p53 and bcl-2, the apoptotic index and the expression of topoisomerase II alpha in patients with inoperable non-small cell lung cancer (NSCLC) treated with high dose radiotherapy. PATIENTS AND METHODS: A number of 161 patients with inoperable NSCLC treated with high dose radiotherapy (60 Gy) were included. Immunohistochemical analysis was used to assess the expression of nuclear p53-protein, topoisomerase II alpha and cytoplasmatic expression of bcl-2, while spontaneous apoptosis was assessed using in situ labeling. The minimal follow up period was 2 years.
RESULTS: Local control did not only depend on the presence of p53 expression, but also on the proportion of p53 positive cells. The most important prognostic factor was the apoptotic index. A high apoptotic index was associated with worse local control, more distant metastases and a significantly worse overall survival. No association was noted between the expression of bcl-2 and topoisomerase II alpha with any of the endpoints.
CONCLUSION: This study indicates that p53 expression and the apoptotic index are prognostic factors with regard to local control in patients with inoperable NSCLC treated with radiotherapy and by combining these 2 factors, a clinically relevant estimation of the local control probability can be made. The apoptotic index turned out to be the only factor significantly related to survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10927139     DOI: 10.1016/s0167-8140(00)00218-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

2.  Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression.

Authors:  D Dworakowska; E Jassem; J Jassem; A Karmoliński; R Dworakowski; T Wirth; M Gruchała; A Rynkiewicz; J Skokowski; S Yla-Herttuala; K Jaśkiewicz; E Czestochowska
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

3.  Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy: An Institutional Analysis.

Authors:  Amna Sher; Sowmini Medavaram; Barbara Nemesure; Sean Clouston; Roger Keresztes
Journal:  Cancer Manag Res       Date:  2020-08-11       Impact factor: 3.989

Review 4.  Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review.

Authors:  Charalampos Gkogkou; Konstantina Frangia; Muhammad W Saif; Rodoula Trigidou; Konstantinos Syrigos
Journal:  Springerplus       Date:  2014-03-01

Review 5.  Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis.

Authors:  Feifei Na; Jingwen Wang; Cong Li; Lei Deng; Jianxin Xue; You Lu
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

6.  Computed tomography morphologic features of pulmonary adenocarcinoma with brain/bone metastasis.

Authors:  Ki-Eun Hwang; Su-Jin Oh; Chul Park; Se-Jeong Jeon; Jeong-Mi Lee; Byong-Ki Cha; Kwon-Ha Yoon; Eun-Taik Jeong; Hak-Ryul Kim
Journal:  Korean J Intern Med       Date:  2016-02-15       Impact factor: 2.884

7.  Integrative radiogenomic profiling of squamous cell lung cancer.

Authors:  Mohamed E Abazeed; Drew J Adams; Kristen E Hurov; Pablo Tamayo; Chad J Creighton; Dmitriy Sonkin; Andrew O Giacomelli; Charles Du; Daniel F Fries; Kwok-Kin Wong; Jill P Mesirov; Jay S Loeffler; Stuart L Schreiber; Peter S Hammerman; Matthew Meyerson
Journal:  Cancer Res       Date:  2013-08-26       Impact factor: 12.701

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.